Technical Analysis for ANRO - Alto Neuroscience, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 4.03 | 0.50% | 0.02 |
ANRO closed up 0.5 percent on Wednesday, October 30, 2024, on 84 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 0.50% | |
| Calm After Storm | Range Contraction | 0.50% | |
| NR7 | Range Contraction | 0.50% |
| Alert | Time |
|---|---|
| Possible NR7 | about 14 hours ago |
| Up 3% | about 16 hours ago |
| Up 2% | about 16 hours ago |
| 60 Minute Opening Range Breakout | about 17 hours ago |
| 60 Minute Opening Range Breakdown | about 18 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/21/2024
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto's Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia, and other mental health conditions.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Neuroscience Schizophrenia Biomarkers Depression Neurophysiology Electroencephalography Post Traumatic Stress Disorder Neurocognition Ptsd
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Neuroscience Schizophrenia Biomarkers Depression Neurophysiology Electroencephalography Post Traumatic Stress Disorder Neurocognition Ptsd
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 24.0 |
| 52 Week Low | 3.9 |
| Average Volume | 784,146 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 11.60 |
| 20-Day Moving Average | 10.24 |
| 10-Day Moving Average | 8.26 |
| Average True Range | 1.16 |
| RSI (14) | 22.48 |
| ADX | 35.97 |
| +DI | 15.08 |
| -DI | 52.39 |
| Chandelier Exit (Long, 3 ATRs) | 11.57 |
| Chandelier Exit (Short, 3 ATRs) | 7.37 |
| Upper Bollinger Bands | 18.62 |
| Lower Bollinger Band | 1.85 |
| Percent B (%b) | 0.13 |
| BandWidth | 163.77 |
| MACD Line | -2.08 |
| MACD Signal Line | -1.04 |
| MACD Histogram | -1.041 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.38 | ||||
| Resistance 3 (R3) | 4.38 | 4.26 | 4.32 | ||
| Resistance 2 (R2) | 4.26 | 4.17 | 4.26 | 4.30 | |
| Resistance 1 (R1) | 4.14 | 4.11 | 4.20 | 4.15 | 4.28 |
| Pivot Point | 4.02 | 4.02 | 4.05 | 4.02 | 4.02 |
| Support 1 (S1) | 3.91 | 3.93 | 3.97 | 3.91 | 3.78 |
| Support 2 (S2) | 3.79 | 3.88 | 3.79 | 3.76 | |
| Support 3 (S3) | 3.67 | 3.79 | 3.74 | ||
| Support 4 (S4) | 3.68 |
